Vertex Pharmaceuticals has led a series B round for Genomics, a spinout from University of Oxford that also attracted Oxford Sciences Innovation and IP Group.
Genomics, a UK-based genetic data science spinout from University of Oxford, closed a £25m ($32.5m) series B round today featuring university venture fund Oxford Sciences Innovation.
Pharmaceutical firm Vertex Pharmaceuticals led the round, while commercialisation firm IP Group, Woodford Investment Management, Invesco Perpetual, Lansdowne Partners and Tanarra also took part.
Founded in 2014, Genomics has built an analytics platform that uses machine learning to scour more than 100 billion genomic data points in order to predict what impact a given therapy will have.
The spinout will use the money to drive expansion efforts and further develop its database. Vertex has signed a collaboration agreement with Genomics to develop medicines for patients suffering from serious diseases.
Genomics previously raised $16.2m in a series A round in 2014 backed by University of Oxford, IP Group and its IP Venture Fund II, Invesco Perpetual, Lansdowne Partners, Woodford Investment Management and Wylie Family Trust.
Peter Donnelly, founder and chief executive, Genomics, said: “We are delighted to be supported by such a strong cadre of strategic and institutional investors.
“This fundraising will help us leverage our deep expertise in data science and genetics, our world-leading database of genomic information, and proprietary machine-learning algorithms to help bring greater precision to the discovery of new drugs.”
– A version of this article first appeared on our sister site, Global Corporate Venturing.
